2014
Minimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa - Volume 20, Number 3—March 2014 - Emerging Infectious Diseases journal - CDC
Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, Moll AP, Friedland GH, Sturm AW, Shah NS. Minimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa - Volume 20, Number 3—March 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 394-401. PMID: 24565645, PMCID: PMC3944869, DOI: 10.3201/eid2003.131083.Peer-Reviewed Original ResearchConceptsXDR-TB casesMDR-TBXDR-TBTB casesDrug-resistant Mycobacterium tuberculosis strainsInfectious Diseases journal - CDCDrug-susceptible TBDrug-resistant tuberculosisNon-Beijing strainsDrug-susceptible isolatesMycobacterium tuberculosis strainsStrain typesStrain prevalenceRetrospective studyHigh incidenceBeijing strainsTuberculosis strainsSpoligotype patternsPredominant strainMultidrugStrongest predictorMortalityTBSurvivalHIV
2012
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibiotics, AntitubercularAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patients
2011
Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting
Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, Friedland G, Shah N, Gandhi N. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2011, 15: 1170-1175. PMID: 21943840, DOI: 10.5588/ijtld.10.0781.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntitubercular AgentsExtensively Drug-Resistant TuberculosisFamily CharacteristicsFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleMicrobial Sensitivity TestsMiddle AgedPrevalenceProspective StudiesSouth AfricaTime FactorsTuberculosis, Multidrug-ResistantYoung AdultConceptsDrug-resistant tuberculosisHousehold contactsXDR-TBIndex caseMDR-TBPrevalence settingsHigh human immunodeficiency virus (HIV) prevalence settingsMDR-TB index casesHigh HIV prevalence settingsAdult household contactsHousehold contact investigationIndex case diagnosisMost secondary casesHIV prevalence settingsRate of MDRDrug susceptibility testingDiagnosis of MDRPublic health activitiesActive tuberculosisNosocomial transmissionContact investigationMedian timeIncidence rateSecondary casesObservational study
2009
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community
Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion In Infectious Diseases 2009, 22: 11-17. PMID: 19532076, PMCID: PMC3013226, DOI: 10.1097/qco.0b013e3283210020.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisHIV patientsHIV communityIntegration of tuberculosisIndependent risk factorCourse of treatmentCommunity-based treatmentHIV careNew rapid diagnosticsRisk factorsClinical careNegative individualsTuberculosisPatientsMultidrugRapid diagnosticsCareTreatmentSusceptibility informationMorbidityHIVInfectionMortalityPhysicians
2006
Sexual risk behaviour among HIV-positive individuals in clinical care in urban KwaZulu-Natal, South Africa
Kiene SM, Christie S, Cornman DH, Fisher WA, Shuper PA, Pillay S, Friedland GH, Fisher JD. Sexual risk behaviour among HIV-positive individuals in clinical care in urban KwaZulu-Natal, South Africa. AIDS 2006, 20: 1781-1784. PMID: 16931945, DOI: 10.1097/01.aids.0000242827.05120.55.Peer-Reviewed Original Research
1996
A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY.
Gourevitch M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, Friedland G, Klein R. A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. American Journal Of Public Health 1996, 86: 1112-5. PMID: 8712270, PMCID: PMC1380622, DOI: 10.2105/ajph.86.8_pt_1.1112.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seronegative patientsHIV-seropositive patientsDrug usersHIV infectionEarly syphilisProspective studyHuman immunodeficiency virus (HIV) infectionHigh-risk sexual activityPercent of HIVImmunodeficiency virus infectionMethadone maintenance treatmentDrug-using womenMultiple sex partnersDiagnosis of syphilisEarly syphilis incidenceFemale drug usersHIV seroconversionHIV seroconvertersMaintenance treatmentIncidence rateIndependent riskVirus infectionSyphilis incidencePatients
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groups
1993
Incubation Period of Human Immunodeficiency Virus
Alcabes P, Muñoz A, Vlahov D, Friedland G. Incubation Period of Human Immunodeficiency Virus. Epidemiologic Reviews 1993, 15: 303-318. PMID: 8174659, DOI: 10.1093/oxfordjournals.epirev.a036122.Peer-Reviewed Original Research